The pharmaceutical industry is under increasing pressure to produce safe, high-quality medicines faster, more cost-effectively, and with full regulatory compliance. Traditional batch-based systems, while proven, struggle to support the vision of continuous and smart manufacturing that regulators like the FDA and EMA are now encouraging.
LabWare 8 has emerged as a pivotal enabler in this shift, combining advanced LIMS capabilities, process automation, and data integration to transform the way pharma companies manufacture, monitor, and release products.
In this case, Zamann Pharma Support was engaged to perform a structured GAP assessment of the Waters Empower CSV documentation, ensuring full alignment with FDA regulations and GAMP guidelines, and providing CAPA-driven recommendations to close compliance gaps and strengthen validation readiness.
We support pharmaceutical teams in implementing, maintaining, and optimizing GMP software, data management systems, and computerized workflows that strengthen compliance, data integrity, and operational efficiency.
It evaluates URS, VMP, IQ/OQ/PQ, traceability, and audit trail records against FDA and GAMP requirements. This reveals missing controls, incomplete validation evidence, and documentation gaps that are not visible in routine reviews.
They typically occur in audit trail review gaps, insufficient electronic signature controls, incomplete change control records, and weak traceability between test scripts and requirements.
Because completeness does not equal compliance. Inspectors focus on lifecycle consistency, risk-based validation alignment, and whether documentation reflects actual system behavior under operational conditions.
